Keros Therapeutics
KROS
161 hedge funds and large institutions have $582M invested in Keros Therapeutics in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 30 reducing their positions, and 40 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 30
3% less call options, than puts
Call options by funds: $10.8M | Put options by funds: $11.2M
5% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 40
1% less funds holding
Funds holding: 163 → 161 (-2)
2.39% less ownership
Funds ownership: 93.1% → 90.72% (-2.4%)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
71% less capital invested
Capital invested by funds: $2.03B → $582M (-$1.45B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$61.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.5M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$28.3M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$27.7M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$23.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$49.2M |
| 2 |
Alkeon Capital Management
New York
|
-$41.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$31.4M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$30.5M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$23M |
KROS Hedge Fund Activity: Q4 2024 in Review
161 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2024, worth a combined $582M — down 71% from $2.03B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of KROS and 38 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 74 added.
The largest buyer was Braidwell, adding an estimated $61.7M. The largest seller was Point72 Asset Management, cutting an estimated $49.2M.
- 161 institutional investors held Keros Therapeutics (KROS) as of Q4 2024, down from 163 in Q3 2024.
- Funds reported $582M of Keros Therapeutics stock for Q4 2024, down 71% quarter-over-quarter.
- 38 funds opened new Keros Therapeutics positions in Q4 2024 and 40 closed out, a net change of -2 holders.
- The largest Keros Therapeutics buyer in Q4 2024 was Braidwell, an estimated $61.7M added.
- The largest Keros Therapeutics seller in Q4 2024 was Point72 Asset Management, an estimated $49.2M sold.
Based on aggregated 13F filings for Q4 2024.